Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study

BACKGROUND: In patients with BRAFV600 mutated unresectable stage IIIc or metastatic melanoma, molecular targeted therapy with combined BRAF/MEK-inhibitor vemurafenib plus cobimetinib has shown a significantly improved progression-free survival and overall survival compared to treatment with vemurafe...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Hiel, Bernies, Haanen, John B.A.G., Stokkel, Marcel P.M., Peeper, Daniel S., Jimenez, Connie R., Beijnen, Jos H., van de Wiel, Bart A., Boellaard, Ronald, van den Eertwegh, Alfons J.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603097/
https://www.ncbi.nlm.nih.gov/pubmed/28915798
http://dx.doi.org/10.1186/s12885-017-3626-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603097/
https://www.ncbi.nlm.nih.gov/pubmed/28915798
http://dx.doi.org/10.1186/s12885-017-3626-5

Ejemplares similares